Experienced in Allergic Conjunctivitis

Yoko Kataoka

Habikino, JP 
Experienced in Allergic Conjunctivitis
Habikino, JP 
OverviewLocationsClinical Research

Overview

Yoko Kataoka practices in Habikino, Japan. Ms. Kataoka is rated as an Experienced expert by MediFind in the treatment of Allergic Conjunctivitis. Her top areas of expertise are Atopic Dermatitis, Giant Papillary Conjunctivitis, Lung Cancer, and Conjunctivitis (Pink Eye).

Her clinical research consists of co-authoring 61 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Allergic Conjunctivitis.

Gender
Female

Locations

Habikino, Japan
Other Locations
Osaka, Japan
Otsu, 5202192, Japan
Kohka City, Japan
Minakuchicho-matoba, Japan
Koka, 5280074, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Japanese Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Japanese Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: August 23, 2023
Intervention Type: Drug
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
View 1 Less Clinical Trial

61 Total Publications

Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.
Journal: Immunotherapy
Published: September 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kataoka's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile